H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $54.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst commented: "At its R&D review day, Biohaven provided comprehensive updates across its programs: Glutamate, myostatin, ion channel, inflammation/immunology, and oncology. Top scientists and physicians were invited to the event to share their insights in each of the spaces. We were impressed with the new data reported from ADC and galactose-deficient IgA1 (Gd-IgA1), and more key catalysts are expected in the next 12 months—giving investors several shots on goal that could each drive significant upside in shares from current levels. Reiterate Buy rating and $54 PT."

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $14.74 yesterday.

You May Also Be Interested In

• BMO Capital Starts Insmed (INSM) at Outperform
• Scotiabank Downgrades Pembina Pipeline Corp. (PPL:CN) (PBA) to Sector Perform
• BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform